Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | JAK1 | P23458 | 2/20 | 0.43 |
| ▸ | TYK2 | P29597 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 3/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21757037 | 0.91 | JAK2 (0.45) | JAK2JAK1TYK2ALDH1A1NPC1 | |
| SCHEMBL21756989 | 0.86 | JAK1 (0.42) | JAK2JAK1TYK2ALDH1A1NPC1 | |
| SCHEMBL12385899 | 0.83 | ALDH1A1 (0.58) | ALDH1A1NPC1EPHX2 | |
| SCHEMBL23584409 | 0.80 | HSD11B1 (0.42) | JAK2JAK1TYK2ALDH1A1EPHX2 | |
| SCHEMBL21757052 | 0.75 | JAK1 (0.43) | JAK2JAK1TYK2ALDH1A1NPC1 | |
| SCHEMBL27253737 | 0.74 | USP2 (0.49) | ALDH1A1EPHX2USP2CYP1A2CYP2C19 | |
| SCHEMBL17176072 | 0.71 | PIK3R1 (0.39) | JAK2JAK1TYK2ALDH1A1NAMPT | |
| SCHEMBL15014464 | 0.71 | ALDH1A1 (0.63) | ALDH1A1NPC1EPHX2 | |
| SCHEMBL12424441 | 0.70 | EPHX2 (0.43) | ALDH1A1NPC1EPHX2ITGB3ITGA2B | |
| SCHEMBL12384790 | 0.70 | CYP2D6 (0.46) | JAK2JAK1TYK2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4105214-A1 | USE OF JAK INHIBITORS IN PREPARATION OF DRUGS FOR TREATING JAK KINASE-RELATED DISEASES | Zhuhai United Laboratories Co., Ltd (CN) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022161205-A1 | ORAL PREPARATION CONTAINING JAK INHIBITOR OR SALT THEREOF OR CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 珠海联邦制药股份有限公司 | 2022-08-04 | — | — | WO | disclosed |
| WO-2021159372-A1 | USE OF JAK INHIBITORS IN PREPARATION OF DRUGS FOR TREATING JAK KINASE-RELATED DISEASES | 珠海联邦制药股份有限公司 | 2021-08-19 | — | — | WO | disclosed |
| EP-3842431-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND APPLICATION THEREOF | Zhuhai United Laboratories Co., Ltd (CN) | 2021-06-30 | — | — | EP | disclosed |
| US-20210155621-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND USE THEREOF | ZHUHAI UNITED LABORATORIES CO., LTD. (CN) | 2021-05-27 | — | — | US | disclosed |
| WO-2020038457-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND APPLICATION THEREOF | 珠海联邦制药股份有限公司 | 2020-02-27 | — | — | WO | disclosed |
| US-9403829-B2 | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use | SIGNAL PHARMACEUTICALS, LLC (US) | 2016-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155621-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND USE THEREOF | JAK1, JAK2, TYK2 | JAK2 2/4885JAK1 1/4885TYK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.